The Office of Psychiatric Clinical Research is designed to support psychiatric research in the clinical setting here at the Department of Psychiatry and Behavioral Neurobiology. Our research division offers several cutting edge resources for Phase II, III and IV studies. The coordination of our clinical trials is of the highest quality. We are supported by experienced investigators and staff dedicated to academic excellence and quality patient care. We have a full-time clinical research staff with regulatory and administrative services and assistance in designing clinical studies and providing referrals for statistical analysis. We provide investigator training in psychiatric rating scales and standardized diagnostic instruments and education in patient recruitment. We have a quality assurance program and facilities for drug storage, physical exams, EKG’s, interviewing, venipuncture and specimen processing. Our expert research team consists of: Roberta May, MA, CCRC – Director; Hollis Ryan, BS, CCRC – Clinical Trials Manager; Samantha White, BS – Clinical Trials Administrator; Emily Hammond, M.Ed. – Project Coordinator; Sherer Thomson, M.Ed.- Project Coordinator and Nick Bossaller, BA – Project Coordinator.
Currently Enrolling Trials:
ADHD
“Evening use of polarized glasses designed to filter out blue light in ADHD-Delayed Circadian Rhythm Disordered patients” Principal Investigator: Rachel Fargason, MD
Alzheimer’s Disease
“A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-Carriers (Wyeth)”. Principal Investigator: F. Cleveland Kinney, MD, PhD
Mood Disorders
“Paliperidone and Lithium in the Treatment of Suicidality – Treatment Indication and Epigenetic Regulation” Principal Investigator: Richard Shelton, MD
“A three-phase study designed to test the efficacy, tolerability and safety of the combination of Ziprasidone with the selective serotonin reuptake inhibitor (SSRI) Escitalopram for patients with Major Depressive Disorder (MDD) that do not sufficiently respond to treatment with Escitalopram” Principal Investigator: Richard Shelton, MD
A Phase 2, Multicenter, “Open-label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adult Patients with Major Depressive Disorder” Principal Investigator: Rachel Fargason, MD
“Validation study of InterSePT Scale for Suicidal Thinking-Plus (ISST-Plus), Sheehan Suicide Tracking Scale (S-STS) and Columbia Suicide Severity Rating Scale (C-SSRS): Consistency of mapping to Columbia Classification Algorithm of Suicide Assessment (C-CASA)” Principal Investigators: Roberta May, MA and Cheryl McCullumsmith, MD
“ Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer and a Classic Mood Stabilizer for Bipolar Disorder” Principal Investigator: Richard Shelton
“Assessment and treatment of impulsivity and thought process disorder in patients with active suicidal ideation and depression” Principal Investigator: Cheryl McCullumSmith
“Development of Post-Traumatic Stress Disorder after Natural Disaster” Principal Investigator: Cheryl McCullumSmith
“A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of desvenlafaxine succinate sustained-release (DVS SR) in the treatment of children and adolescent outpatients with major depressive disorder” PI: James T. Cullinan, DO
“A 6-month, open-label, multi-center, flexible-dose extension study to the B2061032 study to evaluate the safety, tolerability and efficacy of desvenlafaxine succinate sustained-release (DVS SR) tablets in the treatment of children and adolescent outpatients with major depressive disorder” PI: James T. Cullinan, DO
For further information, please contact:
Callahan Eye Foundation Hospital
UAB Department of Psychiatry
Office of Psychiatric Clinical Research
1720 University Blvd Suite H350
Birmingham, AL 35294
Telephone: (205) 934-2484
